SCHEMBL16570558

SCHEMBL16570558

CN(c1nccnc1Cn1ccc2cnc(Nc3ccc(N4CCNCC4)cc3)cc21)S(C)(=O)=O

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ STAT6 P42226 1/20 0.42
▸ FGFR4 P22455 1/20 0.42
▸ JAK2 O60674 10/20 0.41
▸ BRD4 O60885 7/20 0.41
▸ JAK3 P52333 5/20 0.41
▸ JAK1 P23458 2/20 0.41
▸ BRD2 P25440 2/20 0.41
▸ BRD3 Q15059 2/20 0.41
▸ BRDT Q58F21 2/20 0.41
▸ PTK2 Q05397 5/20 0.39
▸ SRPK2 P78362 1/20 0.39
▸ SRPK1 Q96SB4 1/20 0.39
▸ FYN P06241 2/20 0.38
▸ CDK4 P11802 2/20 0.36
▸ CDK6 Q00534 1/20 0.36
▸ WEE1 P30291 1/20 0.36
▸ CCND1 P24385 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16570464 0.90 FGFR4 (0.38) FGFR4JAK2BRD4JAK3JAK1
SCHEMBL16570461 0.90 FGFR4 (0.38) FGFR4JAK2BRD4JAK3JAK1
SCHEMBL16580779 0.89 SRPK1 (0.51) STAT6FGFR4JAK2BRD4JAK3
SCHEMBL16570528 0.87 JAK2 (0.39) FGFR4JAK2BRD4JAK3JAK1
SCHEMBL16570340 0.85 STAT6 (0.58) STAT6FGFR4JAK2BRD4JAK3
SCHEMBL16570204 0.84 JAK2 (0.45) STAT6FGFR4JAK2BRD4JAK3
SCHEMBL16570736 0.81 PTK2 (0.51) JAK2JAK3PTK2SRPK2SRPK1
SCHEMBL16570103 0.80 PTK2 (0.54) STAT6FGFR4JAK2BRD4JAK3
SCHEMBL17958785 0.80 SRPK1 (0.48) JAK2JAK3PTK2SRPK2SRPK1
SCHEMBL16570447 0.80 SRPK1 (0.48) JAK2JAK3PTK2SRPK2SRPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US claimed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO claimed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS SRC, PTK2, FYN STAT6 103/4885FGFR4 385/4885JAK2 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback